PMID- 15848678
OWN - NLM
STAT- MEDLINE
DCOM- 20050926
LR  - 20061115
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 37
IP  - 2
DP  - 2005 Mar
TI  - HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
PG  - 1230-2
AB  - In addition to cytomegalovirus (CMV), activation of other betaherpesviruses, 
      especially human herpesvirus 6 (HHV-6), has been reported in liver transplant 
      patients. The purpose of this study was to investigate the posttransplant 
      HHV-6-DNAemia in relation to CMV-DNAemia in liver transplant patients. Thirty-one 
      adult liver allograft recipients were regularly monitored for CMV and HHV-6 
      during the first 3 months after transplantation. For the diagnosis of CMV 
      infections, pp65-antigenemia assay and quantitative DNA-PCR were used. HHV-6 was 
      demonstrated by using quantitative DNA-PCR and HHV-6 antigenemia test. Altogether 
      253 blood specimens of 31 recipients were analyzed. In addition, CMV and HHV-6 
      specific antigens were demonstrated by immunohistochemistry in liver biopsy 
      specimens in the case of graft dysfunction. Thirteen patients (40%) developed a 
      clinically significant CMV infection, at a mean of 33 days (range 5 to 62 days) 
      after transplantation and were treated with intravenous ganciclovir. The peak 
      viral loads of these symptomatic CMV infections were high (CMV-DNA 34210 +/- 
      37557 copies/mL plasma). Six additional asymptomatic patients demonstrated 
      significantly lower CMV-DNAemia levels (1020 +/- 1008 copies/mL, P < .05), and 
      were not treated. Concurrently with CMV, HHV-6 DNAemia and antigenemia were 
      detected in 17 of 19 patients, mean 11 days (range 6 to 24 days) after 
      transplantation. HHV-6 appeared prior to CMV in most cases (12 of 17). However, 
      the peak viral loads were low (HHV-6-DNA <1500 copies/mL blood), even in the five 
      patients who demonstrated HHV-6 antigens on liver biopsy. All CMV infections were 
      successfully treated with ganciclovir and the CMV DNAemia/antigenemia subsided. 
      HHV-6 also responded to the antiviral treatment, but more slowly and less 
      clearly. In conclusion, HHV-6 activations were common and usually associated with 
      CMV infection in liver transplant patients. Further investigation of the clinical 
      significance of HHV-6 DNAemia/antigenemia is necessary.
FAU - Harma, M
AU  - Harma M
AD  - Department of Virology, Helsinki University Hospital and University of Helsinki, 
      Helsinki, Finland. Maiju.Harma@helsinki.fi
FAU - Loginov, R
AU  - Loginov R
FAU - Piiparinen, H
AU  - Piiparinen H
FAU - Halme, L
AU  - Halme L
FAU - Hockerstedt, K
AU  - Hockerstedt K
FAU - Lautenschlager, I
AU  - Lautenschlager I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Adult
MH  - Cytomegalovirus/*genetics
MH  - Cytomegalovirus Infections/*epidemiology
MH  - DNA, Viral/*blood/genetics
MH  - Follow-Up Studies
MH  - Herpesvirus 6, Human/*genetics
MH  - Humans
MH  - Liver Transplantation/*physiology
MH  - Polymerase Chain Reaction
MH  - Postoperative Complications/*virology
MH  - Postoperative Period
MH  - Roseolovirus Infections/epidemiology
MH  - Time Factors
MH  - Transplantation, Homologous
EDAT- 2005/04/26 09:00
MHDA- 2005/09/27 09:00
CRDT- 2005/04/26 09:00
PHST- 2005/04/26 09:00 [pubmed]
PHST- 2005/09/27 09:00 [medline]
PHST- 2005/04/26 09:00 [entrez]
AID - S0041-1345(04)01441-1 [pii]
AID - 10.1016/j.transproceed.2004.12.004 [doi]
PST - ppublish
SO  - Transplant Proc. 2005 Mar;37(2):1230-2. doi: 10.1016/j.transproceed.2004.12.004.